Eleftheria

[Eleftheria @eldermember]

@SetlistCapital Something is a brewing, I can feel it in me bones!

[Eleftheria @eldermember]

@Theoriatheoria @Mohamed42146618 Nonsense, the data is too strong, it may not even be Pfizer dispite having ROFN

[Eleftheria @eldermember]

@SetlistCapital @CaribouBio https://t.co/Uwwt7T3B9Z seems like the right folks to be talking to, perhaps a preview of what’s the come?

[Drew Galahan @DrewGalahaCFA]

All in the same room?? $CRBU seems like partnering talks have some legs. at minimum a massive validation post EHA data win.

[Eleftheria @eldermember]

@Mohamed42146618 Yup, agree🤞

[Eleftheria @eldermember]

@Mohamed42146618 They need to announce a partnership to fund phase 3!

[Eleftheria @eldermember]

They have no choice but to fund Phase 3 trials. They have runway until 27 but it is arguably more advantageous to lock in a deal now off the tail of their positive data.

Biotech history shows companies that partner or raise on good data before the cash crunch do better than those scrambling near runway end. The clock’s ticking either way. @CaribouBio

[Drew Galahan @DrewGalahaCFA]

All in the same room?? $CRBU seems like partnering talks have some legs. at minimum a massive validation post EHA data win.

[Eleftheria @eldermember]

@CrisprGlenn https://t.co/S5CMP6W5qw

[Eleftheria @eldermember]

@CaribouBio @BIOConvention https://t.co/S5CMP6W5qw 🚀

[Eleftheria @eldermember]

@unicornbiotech Cat got your tongue 😛

[Eleftheria @eldermember]

@unicornbiotech The 17.1 mo mPFS is from proper Kaplan-Meier stats on all 27 patients (handles short follow-up/censoring). Swimmer plots always look like this with mixed outcomes — doesn’t contradict the median. Matches their official release. Standard stuff.

[Eleftheria @eldermember]

Great video which confirms the point if you watch it. Kaplan-Meier calculates median PFS by building the survival curve from all patient data: events (progressions) and censored cases (short bars where the patient hasn’t progressed yet by data cutoff). It doesn’t assume censored patients fail right after their last follow up. With the March 6 cutoff and 27 patients, the curve crosses 50% at 17.1 months. That’s the standard method every oncology trial uses. The numbers are correct bud…

[Eleftheria @eldermember]

@unicornbiotech Ok, care to justify how it’s wrong?

[Eleftheria @eldermember]

@unicornbiotech Care to explain

[Caribou Biosciences @CaribouBio]

We’re pleased to share longer follow-up dose escalation data for CB-011 in patients with relapsed or refractory multiple myeloma.

Learn more during an oral presentation at #EHA2026 and here: https://t.co/UGIYd4Fuck #CellTherapy #CRISPR $CRBU

[Eleftheria @eldermember]

@SetlistCapital @ahenryokc @dadbodfamilyguy 🤔

[Caribou Biosciences @CaribouBio]

#EHA2026 kicks off soon!

Members of our clinical team will be in attendance. We look forward to connecting with the global hematology community and discussing data from our two oral presentations.

Hope to see you there! https://t.co/ajfHZhwDmh
#CRISPR #CellTherapy

[Eleftheria @eldermember]

- **Abstracts released May 12, 2026**: Caribou Biosciences announced EHA 2026 oral presentations for vispa-cel (CB-010) on long-term durability in the ANTLER phase 1 trial roughly one month before the June meeting, matching the post’s timeline.
- **Data rooted in September 2025 cutoff**: The core efficacy results (e.g., ORR 82-86%, CR ~63-64%, 12-month PFS ~51-53%) stem from the November 2025 disclosure with that cutoff; earlier 2026 presentations added translational data but not major new clinical follow-up.
- **EHA focuses on longer-term durability**: Company statements indicate the oral presentation will highlight extended follow-up beyond the initial September 2025 data, providing more mature outcomes on response durability rather than purely recycled prior releases.

[Eleftheria @eldermember]

Bottom line: The big BTC levels happened, but his role in publicly forecasting them exactly as claimed lacks supporting evidence from his own timeline. It’s classic influencer marketing to drive follows/notifications for his ongoing (currently bearish) analysis. Treat it as one opinion among many—always cross-check with price action, on-chain data, and your own research. Crypto and markets are full of confident calls; track records are easy to claim after the fact.

[Eleftheria @eldermember]

@SecKennedy @Gatorade @US_FDA I probably won’t drink a lot of Gatorade but will drink it sometimes now. Halve the sugar without artificial BS and I’ll drink it a lot.